- Open Access
Molecular surveillance of artemisinin resistance falciparum malaria among migrant goldmine workers in Myanmar
Malaria Journal volume 16, Article number: 97 (2017)
Artemisinin resistance has been reported in Greater Mekong Sub-region countries, including Myanmar. After discovery of artemisinin resistance marker (K13), molecular surveillance on artemisinin resistance in endemic regions have been conducted. As the migrant population represents a high percentage of malaria cases, molecular surveillance of artemisinin resistance among migrant workers is of great concern.
A cross-sectional survey was conducted in Shwegyin Township, where migrants work in the goldmines. Blood samples were collected from uncomplicated Plasmodium falciparum-infected migrant workers by active and passive cases screening with rapid diagnostic testing (RDT) and microscopy. Amplification and sequence analysis of artemisinin resistance molecular markers, such as k13, pfarps10, pffd, pfmdr2, pfmrp1, pfrad5, and pfcnbp, were carried out and pfmdr1 copy number analysis was conducted by real-time PCR.
Among the 100 falciparum-infected patients, most were male (90%), of working age (20–40 years) with median parasite density of 11,166 parasites/µL (range 270–110,472 parasites/µL). Artemisinin resistance molecular marker, k13 mutations were detected in (21/100, 21.0%) in which composed of a validated marker, C580Y (9/21, 42.9%) and candidate markers such as P574L (5/21, 23.8%), P667T (5/21, 23.8%) and M476I (2/21, 9.5%). Underlying genetic markers predisposing to become k13 mutants were found as V127M of pfarps10 (41/100, 41.0%), D153Y of pffd (64/100, 64.0%), T484I of pfmdr2 (58/100, 58.0%) and F1390I of pfmrp1 (24/100, 24.0%). The pfmdr1 copy number analysis revealed six copy numbers (1/100, 1.0%), three (2/100, 2.0%), two (8/100, 8.0%) and only one copy number (89/100, 89.0%). Only one sample showed both k13 mutation (P667T) and multiple copy number of pfmdr1.
High mutant rate of artemisinin resistance markers and relatively high pfmdr1 copy number among isolates collected from migrant goldmine workers alert the importance of containment measures among this target population. Clinical and molecular surveillance of artemisinin resistance among migrants should be scaled up.
Artemisinin-based combination therapy (ACT) is the most effective anti-malarial treatment for falciparum malaria . However, artemisinin resistance was reported in clinical studies in Cambodia as early as 2006 , followed by other Southeast Asian counties, including Myanmar, Laos, Thailand, and Vietnam . In Myanmar, delayed clearance of the parasite after treatment with ACT has been reported since 2009 in southern Myanmar  and reduced susceptibility of artesunate was observed in 2010 . In Myanmar, a multifaceted artemisinin resistance containment programme was initiated in 2011  and, according to the global plan for artemisinin resistance containment (GPARC), artemisinin resistance zones were categorized as Tier I: where there was evidence of artemisinin resistance; Tier II: where there was suspected evidence of artemisinin resistance; and Tier III: the remaining malaria prevalence areas . According to the MARC programme, migrant and mobile populations are highly vulnerable and the potential spreader of resistant parasites .
The worldwide burden of malaria has been decreasing significantly and the number of countries moving to malarial elimination is increasing . The World Health Organization (WHO) has initiated a strategy for malaria elimination in the Greater Mekong Sub-region by 2030 . Drug resistance is one of the challenges to successfully achieving this goal . Surveillance of artemisinin resistance along with appropriate action to eliminate resistant strains is important in successfully containment of the resistant parasite. After the discovery of artemisinin resistance molecular markers (k13), worldwide prevalence of these markers was documented [11, 12]. Other markers, such as pfmrp1 (multidrug resistance protein 1 gene), pfcnbp (cyclic nucleotide-binding protein) and pfrad5 (DNA repair protein RAD5 homologue) were also identified as potential drug resistance markers . A genome-wide association study reported that pfarps10 (apicoplast ribosomal protein S10), pffd (ferredoxin), pfmdr2 (multidrug resistance protein 2) and pfcrt (chloroquine resistance transporter) gene mutations are significantly associated with delayed clearance of parasites after ACT, indicating the underlying genetic background for artemisinin resistance .
Migrant and mobile populations are a major concern for malaria transmission and are a target group for the artemisinin containment programme implemented in Myanmar, Laos, Cambodia, Thailand, and Vietnam [15, 16]. Because of the nature of these populations, it is difficult to conduct regular longitudinal monitoring and surveillance of the occurrence of malaria in these groups. In this study, molecular marker analysis was carried out in one gold mining area in Myanmar to assess the status and distribution of artemisinin resistance.
Study design and study population
This cross-sectional analysis study was conducted in Shwegyin (22°20′0″ N, 95°56′0″ E), one township of the Myanmar artemisinin resistance containment (MARC) zone (Fig. 1). According to the 2014 census, a population of 107,462 was living in 2440.1 sq km. As the Shwegyin area is famous for gold mining, migrant and mobile populations are working in the deep forest goldmine and bearing a high burden of malaria as compared to the neighbour township (Fig. 1). Moreover, the majority of reported malaria cases come from the migrant population in Shwegyin (Fig. 2) .
Uncomplicated Plasmodium falciparum-infected samples from migrant goldminers or their family members were collected from Shwegyin during 2013–2015. Active and passive cases detection was carried out for sample collection. All malaria suspected cases were initially screened by rapid diagnostic testing (RDT) followed by microscopy examination of peripheral blood smear. The patients with parasite count more than 500/µL were included in the study although all positive cases were treated according to the national malaria treatment guideline. Whole blood samples were collected in EDTA-coated tubes for further molecular analysis.
DNA extraction, amplification and sequencing
Parasite DNA was extracted from the whole blood using QIAamp DNA Blood Mini Kit (QIAGEN) according to manufacturer’s instruction. A nested PCR approach was designated to amplify target genes using a specific pair of primers (Additional file 1). Amplifications were performed in a reaction mixture that contained 0.25 mM of each dNTP, 10 mM Tris–HCl (pH 9.0), 30 mM KCl, 1.5 mM MgCl2, 1.0 units of Taq polymerase (Bioneer, Seoul, Korea), 0.02 µM primers, and 2 µl of genomic DNA. For target gene amplifications, initial denaturation at 95 °C for 5 min was followed by 35 cycles of 95 °C for 30 s, 58 °C for 1 min (k13, pfarps10, pfmdr2) or 62 °C for 1 min (pffd), 72 °C for 1.5 min, and a final extension of 72 °C for 10 min. Using 1 µL of the nested-1 product as a template, the same conditions were applied for the nested-2 PCR except for an annealing temperature of 60 °C for 1 min (k13, pffd, pfmdr2) or 62 °C for 1 min (pfarps10) and 72 °C for 1 min with 30 cycles.
For pfmrp1, pfcnbp and pfrad5 gene amplification, PCR was performed with an initial denaturation at 94 °C for 5 min and 30 cycles at 94 °C for 30 s, 56 °C for 30 s, and 72 °C for 1 min. After amplification of the targets, PCR clean-up was carried out using MEGAquick-spin DNA fragment Kit purification (iNtRON, Republic of Korea) following manufacturer’s instruction. Purified PCR products were sequenced directly by using each primer for target gene amplification. The deduced amino acid sequences were aligned and analysed with the Lasergene® software (DNASTAR, Madison, WI, USA) using the reference sequences of 3D7 retrieved from Plasmodium data base . The sequence data from this study have been submitted to GenBank under accession numbers KJ956790–KJ956797 and KY195978–195988.
Real-time PCR for copy number analysis of the pfmdr1 gene
Copy number analysis on pfmdr1 genes was carried out according to procedures described previously [19, 20]. Briefly, each 20 μL contained 10 μL of multiplex PCR ROX master mix, 0.3 µM of primers, 0.2 µM of probe, 0.3 µM of forward and reverse β-tubulin gene and 2 µL of template DNA. In each run of real-time PCR, 3D7 and Dd2 strain were used as known control for copy number analysis. The thermal cycling conditions were 95 °C for 5 min and then 40 cycles of 95 °C for 15 s and 58 °C for 1 min by ABI 7500 (Applied Biosystems, Foster City, CA, USA).
All data were double checked and analysed by Microsoft Excel and SPSS (Version 22.0. Armonk, NY: IBM Corp). Prevalence of each molecular markers was separately and combined analysed as percentage. Age group, sex and parasitaemia were analysed for association on prevalence of each molecular markers by Chi square test with 95% confidence interval. Multiple and single copy number of pfmdr1 genes and k13 mutations were analysed with co-occurrence of other molecular markers.
Ethical approval and consent to participate
The study was conducted after receiving ethical approval from the institutional ethical committee, Department of Medical Research, Myanmar (Approval no. 52/ethic/2012). Written consent was taken from all participants. Participation in this study was entirely voluntary.
A total of 100 P. falciparum positive samples were included in this study, and as collection was migrant populations in gold mining areas, most were from men of working age. The median parasite density was 11,166 parasites/µL (range 270–110,472 parasites/µL). The basic demographic characteristics of the participants are shown in Table 1.
All of the samples were well amplified for all the molecular markers. Kelch gene, k13 (PF3D7_1343700) sequences analysis revealed that 21/100 (21%) samples were non-synonymous mutation after amino acid 440. There were only four mutation sites were observed. Among them, C580Y accounted for (9/21, 42.9%), P667T (5/21, 23.8%), P574L (5/21, 23.8%) and M476I (2/21, 9.5%).
Similarly, V127M mutation of pfarps10 (PF3D7_1460900.1) accounted for 41/100 (41.0%), D153Y mutation of pffd (PF3D7_1318100) for (64/100, 64.0%), T484I of pfmdr2 (PF3D7_1447900) for (58/100, 58.0%), F1390I of pfmrp1 (PF3D7_0112200) for (24/100, 24.0%), S1188L of pfcnbp (PF3D7_1417400) for (17/100, 17.0%), S1158A of pfrad5 (PF3D7_1343400) for (46/100, 46.0%), and N1131I of pfrad5 for (7/100, 7.0%) (Table 2).
Pfmdr1 copy number analysis showed that 89/100, 89% were single copy number and overall mean copy number of 1.296. Among the multiple copy number samples, eight samples were two copies, two samples were three copies and one sample was six copy number. There was no correlation on mutations of the molecular markers or multiple copy numbers of the pfmdr1 gene with the age group (p = 0.5310), sex (p = 0.2911) and hyperparasitaemia (p = 0.2311). Based on the co-occurrence of the different mutations among seven markers and pfmdr1 copy number, 54 isotypes were observed (Additional file 2). Only three samples showed no mutation with single copy number of pfmdr1. An additional 11 samples were observed that had only one mutation of molecular markers. Among the multiple copy number of pfmdr1 samples, T484I of pfmdr2 mutation showed 9/11 (81.8%), D153Y of pffd found as 6/11 (54.4%) and pfrad5 accounted for 5/11 (45.5%). A significantly higher mutant rate of pfmdr2 was observed among the pfmdr1 multiple copy number (p = 0.0307) (Fig. 3).
As k13 gene mutation is a well-known marker for artemisinin resistance, co-occurrence of k13 mutants and other marker mutants were also assessed. Among the 21 samples of k13 mutants, D153Y of pffd (9/21, 42.9%), V127M of pfarps (8/21, 38.1%), T484I of pfmdr2 (5/21, 23.8%), F1390I of pfmrp1 (5/21, 23.8%), S1158A of pfrad5 (5/21, 23.8%) and S1188L of pfcnbp (2/21, 9.5%) were observed. The pfmdr2 and pfrad5 mutations were at a higher mutant rate among k13 wild-type samples (p = 0.0004 and p = 0.0217, respectively (Fig. 4).
In this study, a total of 100 uncomplicated falciparum malaria patients from migrant goldminers were included for molecular analysis. Well-known artemisinin resistance molecular marker, k13 genes as well as other markers, including pfarps10, pffd, pfmdr2, pfmrp1, pfcnbp, and pfrad5 genes were analysed. Moreover, to estimate mefloquine or lumefantrine resistance, pfmdr1 copy numbers were assessed.
Currently, k13 is the only molecular markers confirmed by transfection and clinical data [11, 21]. Although more than one hundred of k13 mutations were reported, non-synonymous mutations after amino acid position 440 were found to be linked with artemisinin resistance [21, 22]. In this study, approximately one-fifth of the samples (21%) showed four non-synonymous mutations in k13 genes. Among them, C580Y is predominant (9/21, 42.86%) followed by P574L (5/21, 23.81%), P667T (5/21, 23.81%) and M476I (2/21, 9.523%). The C580Y, a validated marker for artemisinin resistance has been observed in falciparum endemic countries in South–east Asia region [22, 23]. In Myanmar, C580Y mutation was observed in 11% of the samples in Kawthaung, southern Myanmar. Although it was also reported in Kayin State, Myanmar–Thai border area , previous survey in Shwegyin showed no C580Y mutation . Meanwhile, it has been increasing in Thai side of the border area . In this study, C580Y was detected as 9/21 (42.9%) of all non-synonymous mutations in K13 propeller region and might be increasing in prevalence, although the overall proportion of isolates with mutations in the propeller region does not appear to have changed compared to the previous study conducted in the same study site .
Although P667T and M476I were not common k13 mutations, they were also reported as associated markers with delayed parasite clearance after treatment with ACT in Thailand  and Cambodia . Interestingly, in this study, P667T was the first reported k13 mutation in Myanmar, although it was observed as one of the markers showing delayed parasite clearance in Thailand .
According to the genome-wide association study (GWAS) , other markers, such as pfarps10, pffd, pfmdr2, and pfcrt also indicate a genetic background predisposing to become k13 mutant. Moreover, these markers showed equal geographical distribution of k13 mutations . In this study, D153Y of pffd showed the highest mutant rate that accounted for 64%, followed by T484I of pfmdr2 (58%) and V127M of pfarps10 (41%), reflecting similar findings by GWAS at the same study site. Moreover, these markers were also reported in asymptomatic infections among the local residents of this study site . However, there is no enough evidence on the interpretation and mechanism of these markers.
Before discovery of K13 molecular marker, pfmrp1, pfcnbp and pfrad5 were identified as potential markers associated with artemisinin resistance. Among them, pfmrp1 and pfcnbp are denoted as the markers of less certain evidence. The F1980I mutation of pfmrp1 was found as an artemether–lumefantrine combination, reflecting multi-drug resistance status, especially for lumefantrine [29, 30]. However, no mutations in pfmrp1 that showed the delayed clearance of parasite was identified in GWAS. It may be because of the phenotype used in GWAS and the markers are unlikely to be of relevance to artemisinin resistance in Southeast Asia region . Meanwhile, pfcnbp and pfrad5 were reported as potential candidates to assess delayed parasite clearance of parasites as these two proteins are involved in post-replication repair process . However, pfcnbp is a gene annotated as a pseudogene  and it did not appear as an important markers related with delayed parasite clearance in GWAS in South–east Asia region .
The marker that are likely to have been associated with artemisinin resistance only because of the linkage disequilibrium include pfrad5. It is important to understand that mutations in pfrad5 was almost certainly associated with artemisinin resistance  because of the linkage to the C580Y of Cambodia isolates in k13 genes that was close to pfrad5 on chromosome 13. In this study, 46.0, 24.0 and 17.0% were noted as non-synonymous mutations in pfrad5, pfmrp1 and pfcnbp. However, the k13 mutation in Myanmar has a different genetic background to that in Cambodia and it is unable to interpret directly based on these mutations in pfrad5, pfmrp1 and pfcnbp in Myanmar.
The pfmdr1 multiple copy number also linked to resistance to ACT, especially for combinational therapy with mefloquine . Both k13 mutations and pfmdr1 multiple copy in clinical samples increased risk of treatment failure by up to 14 times . In this study, pfmdr1 multiple copy was observed in 11% of the samples, which was higher than a previous multi-site study in Myanmar , but similar to a multi-countries study conducted in Southeast Asia region  and lower than a study conducted in Thailand . Among the pfmdr1 multiple copy number samples, eight were two copies, two were three copies and one sample showed six copies. Only one sample showed both k13 and pfmdr1 multiple copy number. Moreover, only pfmdr2 (T484I) showed the significantly higher mutant rate in pfmdr1 copy number, reflecting potential partner drug resistance.
In this study, artemisinin resistance molecular markers among falciparum-infected samples from migrant goldminers were first reported. There are very few studies focusing on drug resistance in migrant populations although they have been recognized as a target population in containment programmes. High mutant rate of artemisinin resistance molecular marker, k13 in migrant goldmine workers alert to emphasize the surveillance on artemisinin resistance in this target group population. Although high co-occurrence of k13 and pfmdr1 copy number was not observed, a significant 11% of samples with multiple copy number of pfmdr1 showed potential partner drug resistance. Scaling-up of clinical and molecular surveillance of migrant and mobile populations should be emphasized in the strategy to eliminate artemisinin resistance in the Greater Mekong Sub-region.
WHO. Guidelines for treatment of Malaria. Geneva: World Health Organization; 2015.
WHO. Global report on antimalarial drug efficacy and drug resistance: 2000–2010. Geneva: World Health Organization; 2010.
WHO. Status report: artemisinin and artemisinin-based combination therapy resistance. Geneva: World Health Organization; 2016.
Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Lindegardh N, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS ONE. 2013;8:e57689.
WHO. Strategic framework for artemisinin resistance containment in Myanmar (MARC) 2011–2015. Yangon: WHO country office for Myanmar; 2011.
WHO. Emergency response to artemisinin resistance in the Greater Mekong subregion. Regional framework for action 2013–2015. Geneva: World Health Organization; 2013.
Wongsrichanalai C, Sibley CH. Fighting drug-resistant Plasmodium falciparum: the challenge of artemisinin resistance. Clin Microbiol Infect. 2013;19:908–16.
WHO. World malaria report 2015. Geneva: World Health Organization; 2016.
WHO. Strategy for malaria elimination in the Greater Mekong Subregion (2015–2030). Manila: World Health Organization Regional Office for the Western Pacific; 2015.
Lwin KM, Imwong M, Suangkanarat P, Jeeyapant A, Vihokhern B, Wongsaen K. Elimination of Plasmodium falciparum in an area of multi-drug resistance. Malar J. 2015;14:319.
Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.
MalariaGEN Plasmodium falciparum Community Project. Genomic epidemiology of artemisinin resistant malaria. eLife. 2016;5:e08714.
Takala-Harrison S, Clark TG, Jacob CG, Cummings MP, Miotto O, Dondorp AM, et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci USA. 2013;110:240–5.
Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet. 2015;47:226–34.
WHO. Global plan for artemisinin resistance containment (GPARC). Geneva: World Health Organization; 2011.
Carrara VI, Lwin KM, Phyo AP, Ashley E, Wiladphaingern J, Sriprawat K, et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai–Myanmar border, 1999–2011: an observational Study. PLoS Med. 2013;10:e1001398.
VBDC. Vector borne disease control center report. Naypyitaw: Ministry of Health; 2014.
PlasmoDB. Plasmodium genomics resource. http://www.plasmodb.org.
Alker AP, Lim P, Sem R, Shan NK, Yi P, Bouth DM, et al. PFMDR1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian–Thai border. Am J Trop Med Hyg. 2007;76:641–7.
Win AA, Imwong M, Kyaw MP, Woodrow CJ, Chotivanich K, Hanboonkunupakarn B, et al. K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar. Malar J. 2016;15:110.
Straimer J, Gnädig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015;347:428–31.
Menard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016;374:2453–64.
Phyo AP, Jittamala P, Nosten FH, Pukrittayakamee S, Imwong M, White NJ, et al. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infect Dis. 2016;16:61–9.
Nyunt MH, Hlaing T, Oo HW, Tin-Oo L-LK, Phway HP, Wang B, et al. Molecular assessment of artemisinin resistance markers, polymorphisms in the K13 propeller, and a multidrug-resistance gene in the eastern and western border areas of Myanmar. Clin Infect Dis. 2015;60:1208–15.
Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15:415–21.
Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.
Anderson TJC, Nair S, McDew-White M, Cheeseman IH, Nkhoma S, Bilgic F, et al. Population parameters underlying an ongoing soft sweep in southeast Asian malaria parasites. Mol Biol Evol. 2017;34:131–44.
Nyunt MH, Shein TZ, Zaw NN, Han SS, Muh F, Lee SK, et al. Molecular evidence of drug resistance in asymptomatic malaria infections, Myanmar, 2015. Emerg Infect Dis. 2017;23:517–20.
Veiga MI, Ferreira PE, Jörnhagen L, Malmberg M, Kone A, Schmidt BA, et al. Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance. PLoS ONE. 2011;6:e20212.
Gupta B, Xu S, Wang Z, Sun L, Miao J, Cui L, et al. Plasmodium falciparum multidrug resistance protein 1 (pfmrp1) gene and its association with in vitro drug susceptibility of parasite isolates from north-east Myanmar. J Antimicrob Chemother. 2014;69:2110–7.
Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, et al. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J. 2009;8:11.
Srimuang K, Miotto O, Lim P, Fairhurst RM, Kwiatkowski DP, Woodrow CJ, et al. Analysis of anti-malarial resistance markers in pfmdr1 and pfcrt across Southeast Asia in the Tracking Resistance to Artemisinin Collaboration. Malar J. 2016;15:541.
MHN, BW, YH and E-TH conceived and designed the study; KTH, KMA and KHA collected field samples and field data management; MHN, BW, JHH, and SKL performed experiments and analysed the data; MHN and BW wrote the manuscript. All authors read and approved the final manuscript.
The authors express their gratitude to the Department of Medical Research and Department of Health for allowing this study. The authors also thank the participants in this study and staff from the Parasitology Research Division, Department of Medical Research for sample collection in the field. The authors thank Takafumi Tsuboi (Ehime University, Japan) for providing Dd2 gDNA of P. falciparum.
The authors declare that they have no competing interests.
Availability of data and materials
The datasets analysed in this study are available from the research team but restrictions may apply to the availability of data, which were used under license of the current study, and so are not publicly available. However, data are available from the corresponding authors upon reasonable request and with the permission of the original research team.
Ethics approval and consent to participate
The study was conducted only after receiving the ethical approval from institutional ethical committee, Department of Medical Research, Myanmar (Approval no. 52/ethic/2012). Written consent was taken from all participants. Participation in this study was entirely voluntary.
This study was supported by the Korea International Cooperation Agency (KOICA), the National Research Foundation of Korea (2013K1A3A9A01043836 and NRF-2014R1A2A1A11052079), Ministry of Science, ICT and Future Planning, Republic of Korea.
Myat Htut Nyunt and Bo Wang are co first authors
Additional file 2. Isotypes based on co-occurance of the different mutations among seven markers and Pfmdr1 copy number
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Nyunt, M.H., Wang, B., Aye, K.M. et al. Molecular surveillance of artemisinin resistance falciparum malaria among migrant goldmine workers in Myanmar. Malar J 16, 97 (2017). https://doi.org/10.1186/s12936-017-1753-8
- Artemisinin resistance
- Molecular surveillance